# DeLLphi-307 (NCT06502977)

> Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

No report yet. It can be ordered.

- Drugs tested: tarlatamab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06502977
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Extensive Stage Small Cell Lung Cancer
- Interventions: Tarlatamab
- Enrollment: 32
- Primary outcome: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

## Indexed commentary on DeLLphi-307 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=dellphi-307-nct06502977
